Studies have indicated that, compared to mutation-positive patients, those without STK11 mutations experience a median delay of 5.5 years in the age at first treatment (18.5 years vs. 13.0 years), along with a 47% reduction in the incidence of intussusception and a 30% decrease in polyp burden (10). The gene discussed is STK11; the disease is polyp.